Clinical pharmacology and therapeutics
July 1, 2026
Tijana Stojanovic, Kent W Nilsson, Robert Fredriksson et al.
Interest in ayahuasca and its main component, N,N-Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited. We therefore systematically examined registered interventional trials of DMT, ayahuasca, and DMT combined with...
Clinical pharmacology and therapeutics
February 1, 2025
Ksenia A Vekhova, Eugenia D Namiot, Jörgen Jonsson et al.
43 citations
Ketamine has a long and very eventful pharmacological history. Its enantiomer, esketamine ((S)-ketamine), was approved by the US Food and Drug Administration (FDA) and EMA for patients with treatment-resistant depression (TRD) in 2019. The number of approved indications for ketamine and esketamine continues to increase, as well as the number of clinical trials. This analysis provides a...
Cellular and molecular neurobiology
January 2010
Anna M S Kindlundh-Högberg, Chris Pickering, Grzegorz Wicher et al.
Ecstasy, 3,4-methylenedioxymetamphetamine (MDMA), is a recreational drug used among adolescents, including young pregnant women. MDMA passes the placental barrier and may therefore influence fetal development. The aim was to investigate the direct effect of MDMA on cortical cells using dissociated CNS cortex of rat embryos, E17. The primary culture was exposed to a single dose of MDMA and...
BMC Neuroscience
April 17, 2008
Anna M.s. Kindlundh-Högberg, Anna Blomqvist, Rana Malki et al.
40 citations
Repeated intermittent MDMA administration induces neuroadaptive changes in gene-transcript expressions of glutamatergic NMDA and AMPA receptor subunits, metabotropic receptors and transporters in regions of the brain regulating reward-related associative learning, cognition, and memory and neuro-endocrine functions.
Neurotoxicology
November 2007
Anna M S Kindlundh-Högberg, Helgi B Schiöth, Per Svenningsson
The popular recreational drug, 3,4-methylenedioxymethamphetamine (MDMA) is often taken as intermittent binges by adolescents at dance clubs. The neurobiological mechanisms that underlie MDMA-induced psychiatric conditions are still poorly understood. In the present study, mimicking adolescent patterns of administration, repeated intermittent MDMA binges (3x5 mg/(kg day) given 3h apart, every...